Heed Cardiac Risk of Bruton Tyrosine Kinase Inhibitors for CLL Heed Cardiac Risk of Bruton Tyrosine Kinase Inhibitors for CLL

Experts are urging caution regarding the cardiac risks of Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia.MDedge News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news